# US 2026/0125410 A1 · Molecular degraders of extracellular proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0125410 A1
- Document ID: US20260125410A1
- Status: Published application
- Kind: A1
- Application number: 19/052,899
- Filed: 2025-02-13
- Published: 2026-05-07
- Earliest claimed: 2021-08-27
- Applicants: Yale University
- Inventors: David CAIANIELLO; Edward DERAMON; David SPIEGEL
- Web page: https://patentgrep.com/patent/US20260125410A1

## CPC

- C07H 15/18: Acyclic radicals, substituted by carbocyclic rings
- C07H 15/26: Acyclic or carbocyclic radicals, substituted by hetero rings
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C07D 225/08: condensed with two six-membered rings
- C07H 15/08: Polyoxyalkylene derivatives
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-β1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.

## Claims

### Claim 1

A compound of Formula I, or a pharmaceutically acceptable salt thereof, having the structure:
wherein:
is a connecting linker between LA and LB with the structure
wherein LA and LB are covalently bonded to either of the open valences in
shown by the wavy lines;
LA is an asialoglycoprotein receptor (ASGPR) binding moiety with the structure
LB is an anti-β1AR binding moiety with the structure
AA is an amino acid sequence at least 80% homologous to SEQ ID NO: 1;
each occurrence of RG1′ is independently
each occurrence of RG1 is independently H or
each occurrence of ZG is:
AG is
RG2 is H;
RG3 is C(═O)CH3;
each occurrence of XG is independently selected from the group consisting of one or more of —CH2—, —C(═O)—, —NH—, and —O—;
m is 2, 3, 4, 5, 6, 7, 8, 9, or 10;
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; and
p is 1, 2, 3, or 4.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Formula I has the structure:

### Claim 3 (depends on 1)

The compound of claim 1, wherein Formula I has the structure:

### Claim 4 (depends on 1)

The compound of claim 1, wherein AA is a (6,12) cyclic peptide in which the cysteine residues at positions 6 and 12 in AA form a disulfide bond.

### Claim 5 (depends on 1)

The compound of claim 1, wherein AA is at least 95% homologous to SEQ ID NO:1.

### Claim 6 (depends on 1)

The compound of claim 1, wherein AA is an amino acid sequence of SEQ ID NO: 1.

### Claim 7 (depends on 1)

A composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 8 (depends on 2)

A composition comprising the compound of claim 2, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 9 (depends on 3)

A composition comprising the compound of claim 3, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 10 (depends on 4)

A composition comprising the compound of claim 4, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 11 (depends on 5)

A composition comprising the compound of claim 5, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 12 (depends on 6)

A composition comprising the compound of claim 6, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
